Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
helicobacter pylori vaccine · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| 6 | EXPERIMENTAL | - |
| 7 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| helicobacter pylori vaccine | BIOLOGICAL | Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly |
| Placebo | BIOLOGICAL | Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly |
Inclusion Criteria: * Healthy * Ages 18-40 * Negative for H. pylori infection * Contraception for females Exclusion Criteria: * Present or past H. pylori infection * Medically significant gastroduodenal disease * Recent corticosteroid use * Bleed diathesis * Use of antibiotics used to treat H. py...
The Helicobacter pylori vaccine is an investigational vaccine developed by Novartis AG (ticker NVS) for Helicobacter pylori infection. It is designed to prevent or treat H. pylori, a bacterium linked to gastritis, gastroduodenal ulcers, gastric cancer, and lymphoma. The vaccine is in Phase 1 clinical development.
The Helicobacter pylori vaccine is being developed for Helicobacter pylori infection and associated conditions, including gastritis, gastric cancer, gastroduodenal ulcers, and lymphoma. It is intended to prevent or treat these conditions by targeting the H. pylori bacterium. The vaccine is investigational and not approved for use.
The Helicobacter pylori vaccine is developed by Novartis AG, which trades under the ticker NVS. The vaccine originated from Chiron's investigational program, as referenced in the Phase 1 trial title. Novartis is the company responsible for its development.
The Helicobacter pylori vaccine is in Phase 1 clinical development. It has completed one Phase 1 trial with 113 participants. As an investigational vaccine, it has not been approved by the FDA or any regulatory agency for commercial use.
The Helicobacter pylori vaccine has been studied in one completed Phase 1 trial, NCT00613665, titled "Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults." The trial enrolled 113 healthy adult volunteers in Germany and was randomized and placebo-controlled.